Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Buys Shares of 1,331 AstraZeneca PLC (NASDAQ:AZN)

by · The Markets Daily

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 1,331 shares of the company’s stock, valued at approximately $101,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of AstraZeneca by 17.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after buying an additional 9,002,450 shares during the period. Capital World Investors boosted its stake in shares of AstraZeneca by 0.3% in the 1st quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock valued at $634,525,000 after buying an additional 29,497 shares during the period. Envestnet Asset Management Inc. boosted its stake in shares of AstraZeneca by 16.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock valued at $266,565,000 after buying an additional 488,644 shares during the period. Clearbridge Investments LLC lifted its stake in AstraZeneca by 5.8% during the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after purchasing an additional 186,010 shares during the last quarter. Finally, Fayez Sarofim & Co lifted its stake in AstraZeneca by 4.7% during the first quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock worth $202,588,000 after purchasing an additional 134,784 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

AZN has been the subject of several recent analyst reports. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Finally, TD Cowen boosted their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $89.75.

View Our Latest Report on AstraZeneca

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $72.83 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The stock has a 50 day moving average of $79.77 and a two-hundred day moving average of $78.64. The stock has a market cap of $225.82 billion, a P/E ratio of 35.18, a P/E/G ratio of 1.39 and a beta of 0.46.

AstraZeneca Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Recommended Stories